Overview of global approval of new drugs in December
-
Last Update: 2020-01-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
(2020 / 01 / 14) the implementation of new medical insurance product reimbursement restrictions faces great challenges; the three approved drugs and R & D pipelines of SMO inhibitors are summarized; nmpa issues 2446 reference preparation catalogue analysis; CDE publicity has not reviewed the reference preparation; 55 pharmaceutical enterprises publish the annual report performance forecast, of which 33 enterprises have the performance forecast Let's find out Close up 200% Hedgehog (Hh) is getting hotter and hotter There is no shortage 20 more than those publicized by CDE in the early stage There are many heavy innovative drugs on the market around the world China and the United States are the most be all eagerness to see it The number of approved treatments will double.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
